Yeh ML, Liang PC, Huang CI, et al. - This study’s findings demonstrate that individuals with resolved hepatitis B virus (HBV) infection were at minimal risk of HBsAg seroreversion, unless with prior anti-HBV treatment experience. Fortunately, it was transient and clinically non-relevant even with a reappearance of HBsAg.

• Researchers recruited a total of 7,630 individuals, 5158 (67.6%) individuals had positive anti-HBs at baseline.

• In 84 individuals, HBsAg seroreversion occurred during 42,815 person-year follow-ups with an annual incidence of 0.2% and a 10-year cumulative risk of 1.9%.

• Compared with anti-HBV treatment-naive individuals, anti-HBV treatment-experienced individuals had a significantly higher risk of HBsAg seroreversion (83/310 [26.8%] vs 1/7320 [0.01%], P < 0.001).

• They found lower rates of positive anti-HBs and anti-HCV in anti-HBV treatment-experienced individuals who developed HBsAg seroreversion.

• In anti-HBV treatment-experienced individuals, both positive anti-HBs (hazard ratio/95% confidence interval: 0.56/0.348–0.903, P = 0.017) and positive anti-HCV (hazard ratio/95% confidence interval: 0.08/0.030–0.234, P < 0.001) were independent factors of HBsAg seroreversion.

• At HBsAg seroreversion, less than 5% of the HBsAg seroreverters had clinical hepatitis flare.

• They found low HBsAg titer, and the only transient reappeared in most of the HBsAg seroreverters.